Login to Your Account

Alexion axes R&D partnerships amid day of mixed Q2 news for biopharma earnings

By Michael Fitzhugh
Staff Writer

Thursday, July 27, 2017

An Alexion Pharmaceuticals Inc. decision to cut ties with Moderna Therapeutics Inc., Blueprint Medicines Corp. and Arbutus Biopharma Corp. led an eventful day of biopharma earnings reports, shaped by better-than-expected results at the rare disease specialist.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription